BR112020005287A2 - composições e métodos para edição de gene ttr e tratar amiloidose attr - Google Patents

Info

Publication number

BR112020005287A2

BR112020005287A2 BR112020005287-6A BR112020005287A BR112020005287A2 BR 112020005287 A2 BR112020005287 A2 BR 112020005287A2 BR 112020005287 A BR112020005287 A BR 112020005287A BR 112020005287 A2 BR112020005287 A2 BR 112020005287A2

Authority

BR

Brazil

Prior art keywords

seq

composition

nos

sequence

ttr

Prior art date

2017-09-29

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 title claims abstract description 645
• 238000000034 method Methods 0.000 title claims abstract description 441
• 101150091380 TTR gene Proteins 0.000 title claims abstract description 63
• 206010002022 amyloidosis Diseases 0.000 title claims abstract description 20
• 230000005782 double-strand break Effects 0.000 claims abstract description 31
• 108020005004 Guide RNA Proteins 0.000 claims description 255
• 150000002632 lipids Chemical class 0.000 claims description 247
• 125000003729 nucleotide group Chemical group 0.000 claims description 189
• 239000002773 nucleotide Substances 0.000 claims description 180
• 230000004568 DNA-binding Effects 0.000 claims description 144
• 239000011230 binding agent Substances 0.000 claims description 139
• 108020004999 messenger RNA Proteins 0.000 claims description 123
• 108091033409 CRISPR Proteins 0.000 claims description 122
• 108020004414 DNA Proteins 0.000 claims description 103
• 210000004027 cell Anatomy 0.000 claims description 90
• 230000004048 modification Effects 0.000 claims description 79
• 238000012986 modification Methods 0.000 claims description 79
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 74
• 239000013598 vector Substances 0.000 claims description 74
• 108700026244 Open Reading Frames Proteins 0.000 claims description 71
• 108090000623 proteins and genes Proteins 0.000 claims description 67
• 150000007523 nucleic acids Chemical class 0.000 claims description 61
• 102000039446 nucleic acids Human genes 0.000 claims description 60
• 108020004707 nucleic acids Proteins 0.000 claims description 60
• 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 54
• 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 54
• 102000004169 proteins and genes Human genes 0.000 claims description 52
• 210000002966 serum Anatomy 0.000 claims description 50
• 238000011282 treatment Methods 0.000 claims description 49
• 210000003494 hepatocyte Anatomy 0.000 claims description 45
• 230000035772 mutation Effects 0.000 claims description 43
• 230000007935 neutral effect Effects 0.000 claims description 39
• 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 37
• 238000009472 formulation Methods 0.000 claims description 37
• 108091029810 SaRNA Proteins 0.000 claims description 33
• GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 32
• 210000001519 tissue Anatomy 0.000 claims description 32
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 30
• 230000000295 complement effect Effects 0.000 claims description 30
• 238000003780 insertion Methods 0.000 claims description 30
• 230000037431 insertion Effects 0.000 claims description 30
• 239000002105 nanoparticle Substances 0.000 claims description 28
• 102000001049 Amyloid Human genes 0.000 claims description 24
• 108010094108 Amyloid Proteins 0.000 claims description 24
• 238000012217 deletion Methods 0.000 claims description 23
• 230000037430 deletion Effects 0.000 claims description 23
• 229940078677 sarna Drugs 0.000 claims description 23
• 208000024891 symptom Diseases 0.000 claims description 23
• 201000007905 transthyretin amyloidosis Diseases 0.000 claims description 21
• NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 20
• 230000002829 reductive effect Effects 0.000 claims description 20
• 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 19
• 108091027544 Subgenomic mRNA Proteins 0.000 claims description 19
• 238000009825 accumulation Methods 0.000 claims description 19
• 230000008859 change Effects 0.000 claims description 18
• 239000013603 viral vector Substances 0.000 claims description 18
• 238000010354 CRISPR gene editing Methods 0.000 claims description 16
• 230000003941 amyloidogenesis Effects 0.000 claims description 16
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 16
• 206010019280 Heart failures Diseases 0.000 claims description 15
• 235000012000 cholesterol Nutrition 0.000 claims description 15
• 230000001939 inductive effect Effects 0.000 claims description 15
• 210000004185 liver Anatomy 0.000 claims description 15
• 101100154772 Homo sapiens TTR gene Proteins 0.000 claims description 14
• 230000006641 stabilisation Effects 0.000 claims description 14
• 238000011105 stabilization Methods 0.000 claims description 14
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 13
• 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims description 13
• 239000003814 drug Substances 0.000 claims description 13
• 230000006872 improvement Effects 0.000 claims description 13
• 201000001119 neuropathy Diseases 0.000 claims description 13
• 230000007823 neuropathy Effects 0.000 claims description 13
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 13
• 238000004458 analytical method Methods 0.000 claims description 11
• 239000008194 pharmaceutical composition Substances 0.000 claims description 10
• 108020004485 Nonsense Codon Proteins 0.000 claims description 9
• 108091034117 Oligonucleotide Proteins 0.000 claims description 9
• 238000000338 in vitro Methods 0.000 claims description 9
• 210000002381 plasma Anatomy 0.000 claims description 9
• 238000009826 distribution Methods 0.000 claims description 8
• 210000002216 heart Anatomy 0.000 claims description 8
• 230000037434 nonsense mutation Effects 0.000 claims description 8
• 238000002965 ELISA Methods 0.000 claims description 7
• 230000008439 repair process Effects 0.000 claims description 7
• 210000003594 spinal ganglia Anatomy 0.000 claims description 6
• 238000012360 testing method Methods 0.000 claims description 6
• 102220470698 BUD13 homolog_V30P_mutation Human genes 0.000 claims description 5
• 230000000747 cardiac effect Effects 0.000 claims description 5
• 210000001072 colon Anatomy 0.000 claims description 5
• 210000005229 liver cell Anatomy 0.000 claims description 5
• 102200150628 rs151220873 Human genes 0.000 claims description 5
• 102200017272 rs28931576 Human genes 0.000 claims description 5
• 102220128569 rs777178486 Human genes 0.000 claims description 5
• 210000003497 sciatic nerve Anatomy 0.000 claims description 5
• 210000002784 stomach Anatomy 0.000 claims description 5
• 206010007509 Cardiac amyloidosis Diseases 0.000 claims description 4
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
• 239000013642 negative control Substances 0.000 claims description 4
• 230000001575 pathological effect Effects 0.000 claims description 4
• 239000000090 biomarker Substances 0.000 claims description 3
• 238000001574 biopsy Methods 0.000 claims description 3
• 210000002987 choroid plexus Anatomy 0.000 claims description 3
• 238000002565 electrocardiography Methods 0.000 claims description 3
• 238000012744 immunostaining Methods 0.000 claims description 3
• 230000007830 nerve conduction Effects 0.000 claims description 3
• 238000009613 pulmonary function test Methods 0.000 claims description 3
• 210000001525 retina Anatomy 0.000 claims description 3
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims description 2
• 206010036790 Productive cough Diseases 0.000 claims description 2
• 238000003556 assay Methods 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 210000005036 nerve Anatomy 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 201000005572 sensory peripheral neuropathy Diseases 0.000 claims description 2
• 210000003802 sputum Anatomy 0.000 claims description 2
• 208000024794 sputum Diseases 0.000 claims description 2
• 230000006780 non-homologous end joining Effects 0.000 claims 3
• 102220558130 Olfactory receptor 2A1/2A42_V30L_mutation Human genes 0.000 claims 1
• 108010071690 Prealbumin Proteins 0.000 abstract description 209
• 102000009190 Transthyretin Human genes 0.000 abstract 1
• 101710163270 Nuclease Proteins 0.000 description 238
• 102000007584 Prealbumin Human genes 0.000 description 208
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 159
• -1 bicyclic furanose Chemical class 0.000 description 114
• GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 80
• 101000772194 Homo sapiens Transthyretin Proteins 0.000 description 69
• 102000056556 human TTR Human genes 0.000 description 69
• 229920001223 polyethylene glycol Polymers 0.000 description 69
• 229940045145 uridine Drugs 0.000 description 63
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 62
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 62
• 235000018102 proteins Nutrition 0.000 description 51
• 230000000694 effects Effects 0.000 description 37
• 101000941029 Homo sapiens Endoplasmic reticulum junction formation protein lunapark Proteins 0.000 description 35
• 101000991410 Homo sapiens Nucleolar and spindle-associated protein 1 Proteins 0.000 description 35
• 102100030991 Nucleolar and spindle-associated protein 1 Human genes 0.000 description 35
• 230000014509 gene expression Effects 0.000 description 29
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 29
• 235000000346 sugar Nutrition 0.000 description 29
• 150000001413 amino acids Chemical class 0.000 description 27
• 238000006467 substitution reaction Methods 0.000 description 26
• 108020004705 Codon Proteins 0.000 description 24
• 230000003321 amplification Effects 0.000 description 24
• 238000003199 nucleic acid amplification method Methods 0.000 description 24
• 108090000765 processed proteins & peptides Proteins 0.000 description 24
• 102000004196 processed proteins & peptides Human genes 0.000 description 22
• 239000000047 product Substances 0.000 description 22
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 22
• 229930185560 Pseudouridine Natural products 0.000 description 20
• PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 20
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 20
• WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 20
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 20
• PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 20
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 18
• 241000700605 Viruses Species 0.000 description 17
• 235000001014 amino acid Nutrition 0.000 description 17
• 229920001184 polypeptide Polymers 0.000 description 17
• 239000003795 chemical substances by application Substances 0.000 description 16
• 238000010453 CRISPR/Cas method Methods 0.000 description 15
• 102000044159 Ubiquitin Human genes 0.000 description 15
• 108090000848 Ubiquitin Proteins 0.000 description 15
• 206010039509 Scab Diseases 0.000 description 14
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 14
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
• 230000000670 limiting effect Effects 0.000 description 13
• 108010041758 cleavase Proteins 0.000 description 12
• 238000001727 in vivo Methods 0.000 description 12
• ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 11
• 102000004389 Ribonucleoproteins Human genes 0.000 description 11
• 108010081734 Ribonucleoproteins Proteins 0.000 description 11
• 125000000217 alkyl group Chemical group 0.000 description 11
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
• 108091006047 fluorescent proteins Proteins 0.000 description 11
• 102000034287 fluorescent proteins Human genes 0.000 description 11
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 10
• 108020005345 3' Untranslated Regions Proteins 0.000 description 10
• 108020003589 5' Untranslated Regions Proteins 0.000 description 10
• 208000035657 Abasia Diseases 0.000 description 10
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
• 210000004369 blood Anatomy 0.000 description 10
• 239000008280 blood Substances 0.000 description 10
• 229910052799 carbon Inorganic materials 0.000 description 10
• 201000010099 disease Diseases 0.000 description 10
• 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 10
• 239000002777 nucleoside Substances 0.000 description 10
• 229920000642 polymer Polymers 0.000 description 10
• 239000011780 sodium chloride Substances 0.000 description 10
• 206010063409 Acarodermatitis Diseases 0.000 description 9
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 9
• 241000699670 Mus sp. Species 0.000 description 9
• 241000447727 Scabies Species 0.000 description 9
• 108020004459 Small interfering RNA Proteins 0.000 description 9
• 239000007983 Tris buffer Substances 0.000 description 9
• 230000000692 anti-sense effect Effects 0.000 description 9
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 230000008021 deposition Effects 0.000 description 9
• 238000010874 in vitro model Methods 0.000 description 9
• 125000003835 nucleoside group Chemical group 0.000 description 9
• 230000009467 reduction Effects 0.000 description 9
• 208000005687 scabies Diseases 0.000 description 9
• 239000004055 small Interfering RNA Substances 0.000 description 9
• 229940104230 thymidine Drugs 0.000 description 9
• 229940113082 thymine Drugs 0.000 description 9
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
• RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 8
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
• 229930024421 Adenine Natural products 0.000 description 8
• 241000701022 Cytomegalovirus Species 0.000 description 8
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
• 102000005720 Glutathione transferase Human genes 0.000 description 8
• 108010070675 Glutathione transferase Proteins 0.000 description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 description 8
• 241000193996 Streptococcus pyogenes Species 0.000 description 8
• 150000001241 acetals Chemical class 0.000 description 8
• 229960000643 adenine Drugs 0.000 description 8
• 230000027455 binding Effects 0.000 description 8
• 239000000872 buffer Substances 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
• 125000001424 substituent group Chemical group 0.000 description 8
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
• 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 7
• 241000124008 Mammalia Species 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 108091023045 Untranslated Region Proteins 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 230000000875 corresponding effect Effects 0.000 description 7
• 231100000673 dose–response relationship Toxicity 0.000 description 7
• 238000005538 encapsulation Methods 0.000 description 7
• 238000002156 mixing Methods 0.000 description 7
• 238000004806 packaging method and process Methods 0.000 description 7
• 239000002245 particle Substances 0.000 description 7
• 102000040430 polynucleotide Human genes 0.000 description 7
• 108091033319 polynucleotide Proteins 0.000 description 7
• 239000002157 polynucleotide Substances 0.000 description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
• 230000028327 secretion Effects 0.000 description 7
• 238000012384 transportation and delivery Methods 0.000 description 7
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 6
• 102000053602 DNA Human genes 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
• 101150071666 HBA gene Proteins 0.000 description 6
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 6
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 6
• 229960002685 biotin Drugs 0.000 description 6
• 235000020958 biotin Nutrition 0.000 description 6
• 239000011616 biotin Substances 0.000 description 6
• 230000003197 catalytic effect Effects 0.000 description 6
• 239000012636 effector Substances 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 108020001507 fusion proteins Proteins 0.000 description 6
• 102000037865 fusion proteins Human genes 0.000 description 6
• 230000003834 intracellular effect Effects 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 239000000178 monomer Substances 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 230000003612 virological effect Effects 0.000 description 6
• 101150077194 CAP1 gene Proteins 0.000 description 5
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 5
• 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 5
• 101100245221 Mus musculus Prss8 gene Proteins 0.000 description 5
• FZWGECJQACGGTI-UHFFFAOYSA-N N7-methylguanine Natural products NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 5
• 229910019142 PO4 Inorganic materials 0.000 description 5
• 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 5
• 241000700584 Simplexvirus Species 0.000 description 5
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
• 229930006000 Sucrose Natural products 0.000 description 5
• 238000002648 combination therapy Methods 0.000 description 5
• 150000001875 compounds Chemical class 0.000 description 5
• 239000002577 cryoprotective agent Substances 0.000 description 5
• 229940104302 cytosine Drugs 0.000 description 5
• 238000002296 dynamic light scattering Methods 0.000 description 5
• 210000003527 eukaryotic cell Anatomy 0.000 description 5
• 125000005647 linker group Chemical group 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 235000021317 phosphate Nutrition 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 238000012163 sequencing technique Methods 0.000 description 5
• 150000003384 small molecules Chemical class 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 239000003381 stabilizer Substances 0.000 description 5
• 239000005720 sucrose Substances 0.000 description 5
• 150000008163 sugars Chemical class 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 230000035897 transcription Effects 0.000 description 5
• 230000002103 transcriptional effect Effects 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• 241000701161 unidentified adenovirus Species 0.000 description 5
• CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 4
• UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 4
• NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 4
• 241000604451 Acidaminococcus Species 0.000 description 4
• 241000093740 Acidaminococcus sp. Species 0.000 description 4
• 108010085238 Actins Proteins 0.000 description 4
• 108010088751 Albumins Proteins 0.000 description 4
• 108020005544 Antisense RNA Proteins 0.000 description 4
• 241000180579 Arca Species 0.000 description 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 4
• 241000589599 Francisella tularensis subsp. novicida Species 0.000 description 4
• 102000029812 HNH nuclease Human genes 0.000 description 4
• 108060003760 HNH nuclease Proteins 0.000 description 4
• 102220622871 Hemoglobin subunit delta_V30L_mutation Human genes 0.000 description 4
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
• 241000689670 Lachnospiraceae bacterium ND2006 Species 0.000 description 4
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 241000588650 Neisseria meningitidis Species 0.000 description 4
• 102000035195 Peptidases Human genes 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• 108091093037 Peptide nucleic acid Proteins 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 108700008625 Reporter Genes Proteins 0.000 description 4
• 102000002669 Small Ubiquitin-Related Modifier Proteins Human genes 0.000 description 4
• 108010043401 Small Ubiquitin-Related Modifier Proteins Proteins 0.000 description 4
• 108010090804 Streptavidin Proteins 0.000 description 4
• 241000187191 Streptomyces viridochromogenes Species 0.000 description 4
• 241000203587 Streptosporangium roseum Species 0.000 description 4
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
• 102000002933 Thioredoxin Human genes 0.000 description 4
• 108091023040 Transcription factor Proteins 0.000 description 4
• 102000040945 Transcription factor Human genes 0.000 description 4
• 108020004566 Transfer RNA Proteins 0.000 description 4
• 102100021012 Ubiquitin-fold modifier 1 Human genes 0.000 description 4
• 101710082264 Ubiquitin-fold modifier 1 Proteins 0.000 description 4
• 101710082247 Ubiquitin-like protein 5 Proteins 0.000 description 4
• 102100030580 Ubiquitin-like protein 5 Human genes 0.000 description 4
• 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 4
• 102100031319 Ubiquitin-related modifier 1 Human genes 0.000 description 4
• 101710144315 Ubiquitin-related modifier 1 Proteins 0.000 description 4
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
• 230000002776 aggregation Effects 0.000 description 4
• 238000004220 aggregation Methods 0.000 description 4
• 125000003545 alkoxy group Chemical group 0.000 description 4
• 125000003118 aryl group Chemical group 0.000 description 4
• 108091092356 cellular DNA Proteins 0.000 description 4
• 102000021178 chitin binding proteins Human genes 0.000 description 4
• 108091011157 chitin binding proteins Proteins 0.000 description 4
• 238000010367 cloning Methods 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 4
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
• 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 4
• 230000002616 endonucleolytic effect Effects 0.000 description 4
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
• 108010021843 fluorescent protein 583 Proteins 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 230000001965 increasing effect Effects 0.000 description 4
• 238000011330 nucleic acid test Methods 0.000 description 4
• 150000003833 nucleoside derivatives Chemical class 0.000 description 4
• 239000010452 phosphate Substances 0.000 description 4
• 239000002953 phosphate buffered saline Substances 0.000 description 4
• 229910052698 phosphorus Inorganic materials 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 230000017854 proteolysis Effects 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 108010054624 red fluorescent protein Proteins 0.000 description 4
• 108060008226 thioredoxin Proteins 0.000 description 4
• 229940094937 thioredoxin Drugs 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 108091005957 yellow fluorescent proteins Proteins 0.000 description 4
• BBGNINPPDHJETF-UHFFFAOYSA-N 5-heptadecylresorcinol Chemical compound CCCCCCCCCCCCCCCCCC1=CC(O)=CC(O)=C1 BBGNINPPDHJETF-UHFFFAOYSA-N 0.000 description 3
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 3
• 239000013607 AAV vector Substances 0.000 description 3
• 102000007469 Actins Human genes 0.000 description 3
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
• 101150014715 CAP2 gene Proteins 0.000 description 3
• 208000031229 Cardiomyopathies Diseases 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 3
• NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 206010013975 Dyspnoeas Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 241000713666 Lentivirus Species 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 101100260872 Mus musculus Tmprss4 gene Proteins 0.000 description 3
• 102000002508 Peptide Elongation Factors Human genes 0.000 description 3
• 108010068204 Peptide Elongation Factors Proteins 0.000 description 3
• 241000288906 Primates Species 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 3
• 108091081024 Start codon Proteins 0.000 description 3
• 238000011374 additional therapy Methods 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 125000003282 alkyl amino group Chemical group 0.000 description 3
• 230000001430 anti-depressive effect Effects 0.000 description 3
• 239000000935 antidepressant agent Substances 0.000 description 3
• 229940005513 antidepressants Drugs 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 125000004429 atom Chemical group 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000002567 autonomic effect Effects 0.000 description 3
• 108010006025 bovine growth hormone Proteins 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 238000007847 digital PCR Methods 0.000 description 3
• 125000005240 diheteroarylamino group Chemical group 0.000 description 3
• 239000002934 diuretic Substances 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 230000037433 frameshift Effects 0.000 description 3
• 238000010362 genome editing Methods 0.000 description 3
• 102000018146 globin Human genes 0.000 description 3
• 108060003196 globin Proteins 0.000 description 3
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
• 229910052736 halogen Inorganic materials 0.000 description 3
• 230000002440 hepatic effect Effects 0.000 description 3
• 125000005241 heteroarylamino group Chemical group 0.000 description 3
• 229910052739 hydrogen Inorganic materials 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• 238000007481 next generation sequencing Methods 0.000 description 3
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
• 229940127073 nucleoside analogue Drugs 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 150000003904 phospholipids Chemical class 0.000 description 3
• 125000004437 phosphorous atom Chemical group 0.000 description 3
• 150000003230 pyrimidines Chemical class 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 150000003291 riboses Chemical class 0.000 description 3
• 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 150000003431 steroids Chemical class 0.000 description 3
• 125000000547 substituted alkyl group Chemical group 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 230000032258 transport Effects 0.000 description 3
• 210000000605 viral structure Anatomy 0.000 description 3
• KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
• SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
• LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 2
• PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
• RFVFQQWKPSOBED-PSXMRANNSA-N 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC RFVFQQWKPSOBED-PSXMRANNSA-N 0.000 description 2
• IJFVSSZAOYLHEE-UHFFFAOYSA-N 2,3-di(dodecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-UHFFFAOYSA-N 0.000 description 2
• YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 2
• KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• 241000007910 Acaryochloris marina Species 0.000 description 2
• 241001135192 Acetohalobium arabaticum Species 0.000 description 2
• 241001464929 Acidithiobacillus caldus Species 0.000 description 2
• 241000605222 Acidithiobacillus ferrooxidans Species 0.000 description 2
• 241000640374 Alicyclobacillus acidocaldarius Species 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 241000190857 Allochromatium vinosum Species 0.000 description 2
• 241000147155 Ammonifex degensii Species 0.000 description 2
• 241000620196 Arthrospira maxima Species 0.000 description 2
• 240000002900 Arthrospira platensis Species 0.000 description 2
• 235000016425 Arthrospira platensis Nutrition 0.000 description 2
• 241001495183 Arthrospira sp. Species 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 206010061666 Autonomic neuropathy Diseases 0.000 description 2
• 108091005950 Azurite Proteins 0.000 description 2
• NTTIDCCSYIDANP-UHFFFAOYSA-N BCCP Chemical compound BCCP NTTIDCCSYIDANP-UHFFFAOYSA-N 0.000 description 2
• 241000906059 Bacillus pseudomycoides Species 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 102100026189 Beta-galactosidase Human genes 0.000 description 2
• 101710201279 Biotin carboxyl carrier protein Proteins 0.000 description 2
• 101710180532 Biotin carboxyl carrier protein of acetyl-CoA carboxylase Proteins 0.000 description 2
• 241000823281 Burkholderiales bacterium Species 0.000 description 2
• 241000168061 Butyrivibrio proteoclasticus Species 0.000 description 2
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
• 101150005393 CBF1 gene Proteins 0.000 description 2
• 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
• 102000000584 Calmodulin Human genes 0.000 description 2
• 108010041952 Calmodulin Proteins 0.000 description 2
• 102000007590 Calpain Human genes 0.000 description 2
• 108010032088 Calpain Proteins 0.000 description 2
• 241000589875 Campylobacter jejuni Species 0.000 description 2
• 241001496650 Candidatus Desulforudis Species 0.000 description 2
• 241001040999 Candidatus Methanoplasma termitum Species 0.000 description 2
• 241000243205 Candidatus Parcubacteria Species 0.000 description 2
• 241000223282 Candidatus Peregrinibacteria Species 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 108091005944 Cerulean Proteins 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 241000579895 Chlorostilbon Species 0.000 description 2
• JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
• 108091005960 Citrine Proteins 0.000 description 2
• 241000193163 Clostridioides difficile Species 0.000 description 2
• 241000193155 Clostridium botulinum Species 0.000 description 2
• 101100329224 Coprinopsis cinerea (strain Okayama-7 / 130 / ATCC MYA-4618 / FGSC 9003) cpf1 gene Proteins 0.000 description 2
• 241000186216 Corynebacterium Species 0.000 description 2
• 241000065716 Crocosphaera watsonii Species 0.000 description 2
• MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
• 108091005943 CyPet Proteins 0.000 description 2
• 241000159506 Cyanothece Species 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• 208000000059 Dyspnea Diseases 0.000 description 2
• 108091005941 EBFP Proteins 0.000 description 2
• 108091005947 EBFP2 Proteins 0.000 description 2
• 108091005942 ECFP Proteins 0.000 description 2
• 102000001301 EGF receptor Human genes 0.000 description 2
• 108060006698 EGF receptor Proteins 0.000 description 2
• 102100031780 Endonuclease Human genes 0.000 description 2
• 108010042407 Endonucleases Proteins 0.000 description 2
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• 241000326311 Exiguobacterium sibiricum Species 0.000 description 2
• 241000605898 Fibrobacter Species 0.000 description 2
• 241000589602 Francisella tularensis Species 0.000 description 2
• 241000588088 Francisella tularensis subsp. novicida U112 Species 0.000 description 2
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical group OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
• 241000968725 Gammaproteobacteria bacterium Species 0.000 description 2
• KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 2
• 108010060309 Glucuronidase Proteins 0.000 description 2
• 102000053187 Glucuronidase Human genes 0.000 description 2
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 description 2
• 101001082063 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 5 Proteins 0.000 description 2
• 101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 description 2
• 101001045218 Homo sapiens Peroxisomal multifunctional enzyme type 2 Proteins 0.000 description 2
• 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 2
• 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 2
• 101710166699 Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 2
• 102100027356 Interferon-induced protein with tetratricopeptide repeats 5 Human genes 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 241001430080 Ktedonobacter racemifer Species 0.000 description 2
• 238000007397 LAMP assay Methods 0.000 description 2
• 241001112693 Lachnospiraceae Species 0.000 description 2
• 241000904817 Lachnospiraceae bacterium Species 0.000 description 2
• 241000186660 Lactobacillus Species 0.000 description 2
• 241000186679 Lactobacillus buchneri Species 0.000 description 2
• 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
• 241000186606 Lactobacillus gasseri Species 0.000 description 2
• 241001148627 Leptospira inadai Species 0.000 description 2
• 241000186805 Listeria innocua Species 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 101000986081 Macaca mulatta Mamu class I histocompatibility antigen, alpha chain F Proteins 0.000 description 2
• 241000501784 Marinobacter sp. Species 0.000 description 2
• 241000204637 Methanohalobium evestigatum Species 0.000 description 2
• 241000192710 Microcystis aeruginosa Species 0.000 description 2
• 241000190928 Microscilla marina Species 0.000 description 2
• 241000542065 Moraxella bovoculi Species 0.000 description 2
• 101100394291 Mus musculus Hba gene Proteins 0.000 description 2
• 108010021466 Mutant Proteins Proteins 0.000 description 2
• 102000008300 Mutant Proteins Human genes 0.000 description 2
• 102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 description 2
• 102100031911 NEDD8 Human genes 0.000 description 2
• 108700004934 NEDD8 Proteins 0.000 description 2
• 101150107958 NEDD8 gene Proteins 0.000 description 2
• 241000167285 Natranaerobius thermophilus Species 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 241000919925 Nitrosococcus halophilus Species 0.000 description 2
• 241001515112 Nitrosococcus watsonii Species 0.000 description 2
• 241000203619 Nocardiopsis dassonvillei Species 0.000 description 2
• 241001223105 Nodularia spumigena Species 0.000 description 2
• 241000192673 Nostoc sp. Species 0.000 description 2
• 108091007494 Nucleic acid- binding domains Proteins 0.000 description 2
• 102000002488 Nucleoplasmin Human genes 0.000 description 2
• WSDRAZIPGVLSNP-UHFFFAOYSA-N O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O Chemical compound O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O WSDRAZIPGVLSNP-UHFFFAOYSA-N 0.000 description 2
• 101100532088 Oryza sativa subsp. japonica RUB2 gene Proteins 0.000 description 2
• 101100532090 Oryza sativa subsp. japonica RUB3 gene Proteins 0.000 description 2
• 241000606856 Pasteurella multocida Species 0.000 description 2
• 241000142651 Pelotomaculum thermopropionicum Species 0.000 description 2
• 102100022587 Peroxisomal multifunctional enzyme type 2 Human genes 0.000 description 2
• 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
• 241000512220 Polaromonas Species 0.000 description 2
• 241001599925 Polaromonas naphthalenivorans Species 0.000 description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
• 241000878522 Porphyromonas crevioricanis Species 0.000 description 2
• 241001135241 Porphyromonas macacae Species 0.000 description 2
• 241001135219 Prevotella disiens Species 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
• 101100506286 Rattus norvegicus Hba1 gene Proteins 0.000 description 2
• 241000190984 Rhodospirillum rubrum Species 0.000 description 2
• 108091028664 Ribonucleotide Proteins 0.000 description 2
• 241000714474 Rous sarcoma virus Species 0.000 description 2
• 241001063963 Smithella Species 0.000 description 2
• 241000191967 Staphylococcus aureus Species 0.000 description 2
• 101100166144 Staphylococcus aureus cas9 gene Proteins 0.000 description 2
• 241000194022 Streptococcus sp. Species 0.000 description 2
• 241000194020 Streptococcus thermophilus Species 0.000 description 2
• 101100166147 Streptococcus thermophilus cas9 gene Proteins 0.000 description 2
• 241000187747 Streptomyces Species 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 241000123713 Sutterella wadsworthensis Species 0.000 description 2
• 206010042674 Swelling Diseases 0.000 description 2
• 241000192560 Synechococcus sp. Species 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
• 108091028113 Trans-activating crRNA Proteins 0.000 description 2
• 241000589892 Treponema denticola Species 0.000 description 2
• 241000078013 Trichormus variabilis Species 0.000 description 2
• 101710087750 Ubiquitin-like protein ISG15 Proteins 0.000 description 2
• 229910052770 Uranium Inorganic materials 0.000 description 2
• 241000545067 Venus Species 0.000 description 2
• 241000605939 Wolinella succinogenes Species 0.000 description 2
• 241000607479 Yersinia pestis Species 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 241001673106 [Bacillus] selenitireducens Species 0.000 description 2
• 241001531273 [Eubacterium] eligens Species 0.000 description 2
• 239000000370 acceptor Substances 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 229960005305 adenosine Drugs 0.000 description 2
• 239000010441 alabaster Substances 0.000 description 2
• 229940083712 aldosterone antagonist Drugs 0.000 description 2
• 239000002170 aldosterone antagonist Substances 0.000 description 2
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
• 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
• 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
• KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000001961 anticonvulsive agent Substances 0.000 description 2
• 229940011019 arthrospira platensis Drugs 0.000 description 2
• 125000003710 aryl alkyl group Chemical group 0.000 description 2
• 125000001769 aryl amino group Chemical group 0.000 description 2
• 239000002876 beta blocker Substances 0.000 description 2
• 229940097320 beta blocking agent Drugs 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 108091005948 blue fluorescent proteins Proteins 0.000 description 2
• 229910000085 borane Inorganic materials 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 101150059443 cas12a gene Proteins 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 108020001778 catalytic domains Proteins 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 239000006143 cell culture medium Substances 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 239000007979 citrate buffer Substances 0.000 description 2
• 239000011035 citrine Substances 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 108010082025 cyan fluorescent protein Proteins 0.000 description 2
• GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 125000004663 dialkyl amino group Chemical group 0.000 description 2
• 150000001985 dialkylglycerols Chemical class 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 125000004986 diarylamino group Chemical group 0.000 description 2
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
• 229960000616 diflunisal Drugs 0.000 description 2
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
• MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
• 206010013023 diphtheria Diseases 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 230000001882 diuretic effect Effects 0.000 description 2
• 208000002173 dizziness Diseases 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 239000010976 emerald Substances 0.000 description 2
• 229910052876 emerald Inorganic materials 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
• 230000004049 epigenetic modification Effects 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 210000002683 foot Anatomy 0.000 description 2
• 229940118764 francisella tularensis Drugs 0.000 description 2
• 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
• 229940029575 guanosine Drugs 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 150000002367 halogens Chemical class 0.000 description 2
• 230000004217 heart function Effects 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• 125000000623 heterocyclic group Chemical group 0.000 description 2
• 238000011577 humanized mouse model Methods 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 230000015788 innate immune response Effects 0.000 description 2
• 210000005007 innate immune system Anatomy 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 229940039696 lactobacillus Drugs 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000008176 lyophilized powder Substances 0.000 description 2
• 230000002132 lysosomal effect Effects 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 150000002739 metals Chemical class 0.000 description 2
• 210000003470 mitochondria Anatomy 0.000 description 2
• 208000004296 neuralgia Diseases 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 108060005597 nucleoplasmin Proteins 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 230000009437 off-target effect Effects 0.000 description 2
• 210000003463 organelle Anatomy 0.000 description 2
• 229940051027 pasteurella multocida Drugs 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
• 102000028499 poly(A) binding Human genes 0.000 description 2
• 108091023021 poly(A) binding Proteins 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• AJAMRCUNWLZBDF-UHFFFAOYSA-N propyl octadeca-9,12-dienoate Chemical compound CCCCCC=CCC=CCCCCCCCC(=O)OCCC AJAMRCUNWLZBDF-UHFFFAOYSA-N 0.000 description 2
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
• 230000037425 regulation of transcription Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
• 230000033764 rhythmic process Effects 0.000 description 2
• 239000002336 ribonucleotide Substances 0.000 description 2
• 238000011808 rodent model Methods 0.000 description 2
• 101150024074 rub1 gene Proteins 0.000 description 2
• 229910052594 sapphire Inorganic materials 0.000 description 2
• 239000010980 sapphire Substances 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 208000013220 shortness of breath Diseases 0.000 description 2
• 230000005783 single-strand break Effects 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000008961 swelling Effects 0.000 description 2
• TXEIIPDJKFWEEC-UHFFFAOYSA-N tafamidis Chemical compound O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 TXEIIPDJKFWEEC-UHFFFAOYSA-N 0.000 description 2
• 229960001353 tafamidis Drugs 0.000 description 2
• 238000010381 tandem affinity purification Methods 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 108091006106 transcriptional activators Proteins 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• GWBUNZLLLLDXMD-UHFFFAOYSA-H tricopper;dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Cu+2].[Cu+2].[Cu+2].[O-]C([O-])=O.[O-]C([O-])=O GWBUNZLLLLDXMD-UHFFFAOYSA-H 0.000 description 2
• UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
• 239000001226 triphosphate Substances 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 229940035893 uracil Drugs 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
• ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
• KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
• LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 description 1
• FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 1
• UHUSDOQQWJGJQS-QNGWXLTQSA-N 1,2-dioctadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-QNGWXLTQSA-N 0.000 description 1
• KLEGMTRDCCDFJK-XDQSQZFTSA-N 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[hydroxy-[(2R,3R,4R,5R)-2-(hydroxymethyl)-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound COCCO[C@@H]1[C@H](O)[C@@H](COP(O)(=S)O[C@@H]2[C@@H](COP(O)(=S)O[C@@H]3[C@@H](COP(O)(=S)O[C@@H]4[C@@H](COP(O)(=S)O[C@@H]5[C@@H](COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@H]6C[C@@H](O[C@@H]6COP(O)(=S)O[C@@H]6[C@@H](COP(O)(=S)O[C@@H]7[C@@H](COP(O)(=S)O[C@@H]8[C@@H](COP(S)(=O)O[C@@H]9[C@@H](COP(O)(=S)O[C@@H]%10[C@@H](CO)O[C@H]([C@@H]%10OCCOC)n%10cc(C)c(=O)[nH]c%10=O)O[C@H]([C@@H]9OCCOC)n9cc(C)c(N)nc9=O)O[C@H]([C@@H]8OCCOC)n8cc(C)c(=O)[nH]c8=O)O[C@H]([C@@H]7OCCOC)n7cc(C)c(=O)[nH]c7=O)O[C@H]([C@@H]6OCCOC)n6cnc7c6nc(N)[nH]c7=O)n6cnc7c6nc(N)[nH]c7=O)n6cc(C)c(=O)[nH]c6=O)n6cc(C)c(=O)[nH]c6=O)n6cnc7c(N)ncnc67)n6cc(C)c(N)nc6=O)n6cnc7c(N)ncnc67)n6cc(C)c(=O)[nH]c6=O)n6cnc7c6nc(N)[nH]c7=O)n6cnc7c(N)ncnc67)n6cnc7c(N)ncnc67)O[C@H]([C@@H]5OCCOC)n5cnc6c(N)ncnc56)O[C@H]([C@@H]4OCCOC)n4cc(C)c(=O)[nH]c4=O)O[C@H]([C@@H]3OCCOC)n3cc(C)c(N)nc3=O)O[C@H]([C@@H]2OCCOC)n2cc(C)c(N)nc2=O)O[C@H]1n1cc(C)c(N)nc1=O KLEGMTRDCCDFJK-XDQSQZFTSA-N 0.000 description 1
• RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
• ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
• FZIIBDOXPQOKBP-UHFFFAOYSA-N 2-methyloxetane Chemical compound CC1CCO1 FZIIBDOXPQOKBP-UHFFFAOYSA-N 0.000 description 1
• 150000005007 4-aminopyrimidines Chemical class 0.000 description 1
• ZAOGIVYOCDXEAK-UHFFFAOYSA-N 6-n-methyl-7h-purine-2,6-diamine Chemical compound CNC1=NC(N)=NC2=C1NC=N2 ZAOGIVYOCDXEAK-UHFFFAOYSA-N 0.000 description 1
• 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
• 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
• 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
• 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
• 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
• 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
• 102100027211 Albumin Human genes 0.000 description 1
• 229930188104 Alkylresorcinol Natural products 0.000 description 1
• 108091093088 Amplicon Proteins 0.000 description 1
• 208000037259 Amyloid Plaque Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 206010003658 Atrial Fibrillation Diseases 0.000 description 1
• 239000005485 Azilsartan Substances 0.000 description 1
• 206010069632 Bladder dysfunction Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• 239000002083 C09CA01 - Losartan Substances 0.000 description 1
• 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
• 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
• 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
• 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
• 108091079001 CRISPR RNA Proteins 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 101100173542 Caenorhabditis elegans fer-1 gene Proteins 0.000 description 1
• 241000589986 Campylobacter lari Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 108020004638 Circular DNA Proteins 0.000 description 1
• 108091028075 Circular RNA Proteins 0.000 description 1
• 241000907165 Coleofasciculus chthonoplastes Species 0.000 description 1
• 108020004394 Complementary RNA Proteins 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
• 230000007018 DNA scission Effects 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
• 229940097420 Diuretic Drugs 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 108010061435 Enalapril Proteins 0.000 description 1
• 241000701533 Escherichia virus T4 Species 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• 206010016202 Familial Amyloidosis Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241001617393 Finegoldia Species 0.000 description 1
• 241000192016 Finegoldia magna Species 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 101710113864 Heat shock protein 90 Proteins 0.000 description 1
• 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
• 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
• 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 1
• 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 108010061833 Integrases Proteins 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• 241001134698 Lyngbya Species 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 108060004795 Methyltransferase Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101000772176 Mus musculus Transthyretin Proteins 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 238000011887 Necropsy Methods 0.000 description 1
• 241000588654 Neisseria cinerea Species 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical class O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 description 1
• 239000005480 Olmesartan Substances 0.000 description 1
• 206010031127 Orthostatic hypotension Diseases 0.000 description 1
• 241000192497 Oscillatoria Species 0.000 description 1
• 241000192520 Oscillatoria sp. Species 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241001386755 Parvibaculum lavamentivorans Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 241000983938 Petrotoga mobilis Species 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 102000055027 Protein Methyltransferases Human genes 0.000 description 1
• 108700040121 Protein Methyltransferases Proteins 0.000 description 1
• 241000519590 Pseudoalteromonas Species 0.000 description 1
• 241000590028 Pseudoalteromonas haloplanktis Species 0.000 description 1
• 102000014450 RNA Polymerase III Human genes 0.000 description 1
• 108010078067 RNA Polymerase III Proteins 0.000 description 1
• 108010012974 RNA triphosphatase Proteins 0.000 description 1
• 230000004570 RNA-binding Effects 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 241001501869 Streptococcus pasteurianus Species 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 241000206213 Thermosipho africanus Species 0.000 description 1
• KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
• NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• 108700005077 Viral Genes Proteins 0.000 description 1
• 108010067390 Viral Proteins Proteins 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 241000269368 Xenopus laevis Species 0.000 description 1
• CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
• AVCYYEUQUXOUPI-SADXPQEKSA-N [(3s,3as,6r,6as)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate;phthalazin-1-ylhydrazine;hydrochloride Chemical compound Cl.C1=CC=C2C(NN)=NN=CC2=C1.[O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 AVCYYEUQUXOUPI-SADXPQEKSA-N 0.000 description 1
• JZMUDPGZRWUKIF-UHFFFAOYSA-N [3-[3-(dimethylamino)propoxycarbonyloxy]-13-octanoyloxytridecyl] 3-octylundecanoate Chemical compound C(CCCCCCC)C(CC(=O)OCCC(CCCCCCCCCCOC(CCCCCCC)=O)OC(=O)OCCCN(C)C)CCCCCCCC JZMUDPGZRWUKIF-UHFFFAOYSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 229960002122 acebutolol Drugs 0.000 description 1
• GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical group CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 229960001570 ademetionine Drugs 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
• 125000003342 alkenyl group Chemical group 0.000 description 1
• 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
• 229960002576 amiloride Drugs 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000002431 aminoalkoxy group Chemical group 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical group C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 230000001773 anti-convulsant effect Effects 0.000 description 1
• 239000003416 antiarrhythmic agent Substances 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 229960003965 antiepileptics Drugs 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 238000000149 argon plasma sintering Methods 0.000 description 1
• 210000004507 artificial chromosome Anatomy 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 229960002274 atenolol Drugs 0.000 description 1
• KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical group CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 description 1
• 229960002731 azilsartan Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 229960002781 bisoprolol Drugs 0.000 description 1
• VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
• 229960004064 bumetanide Drugs 0.000 description 1
• 125000001369 canonical nucleoside group Chemical group 0.000 description 1
• 210000000234 capsid Anatomy 0.000 description 1
• 229960000830 captopril Drugs 0.000 description 1
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
• 229960000623 carbamazepine Drugs 0.000 description 1
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 229960002155 chlorothiazide Drugs 0.000 description 1
• 229960001523 chlortalidone Drugs 0.000 description 1
• 239000003593 chromogenic compound Substances 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 238000009295 crossflow filtration Methods 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 150000001982 diacylglycerols Chemical class 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 229960005156 digoxin Drugs 0.000 description 1
• LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
• LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 229960002866 duloxetine Drugs 0.000 description 1
• 229960000873 enalapril Drugs 0.000 description 1
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 229960001208 eplerenone Drugs 0.000 description 1
• JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical group C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
• 229960004563 eprosartan Drugs 0.000 description 1
• OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 210000001808 exosome Anatomy 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 210000003746 feather Anatomy 0.000 description 1
• UJHBVMHOBZBWMX-UHFFFAOYSA-N ferrostatin-1 Chemical compound NC1=CC(C(=O)OCC)=CC=C1NC1CCCCC1 UJHBVMHOBZBWMX-UHFFFAOYSA-N 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 229960003883 furosemide Drugs 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 229960002870 gabapentin Drugs 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 108010064833 guanylyltransferase Proteins 0.000 description 1
• 150000004820 halides Chemical group 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 229960005384 hydralazine hydrochloride Drugs 0.000 description 1
• 229960002003 hydrochlorothiazide Drugs 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 229960001195 imidapril Drugs 0.000 description 1
• KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
• 229960004569 indapamide Drugs 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 229950002218 inotersen Drugs 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 229960002198 irbesartan Drugs 0.000 description 1
• YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
• 210000004731 jugular vein Anatomy 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 229960004773 losartan Drugs 0.000 description 1
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 230000007257 malfunction Effects 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
• 229960002817 metolazone Drugs 0.000 description 1
• 229960002237 metoprolol Drugs 0.000 description 1
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
• 230000027939 micturition Effects 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
• 229960004255 nadolol Drugs 0.000 description 1
• 239000004081 narcotic agent Substances 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 229960000619 nebivolol Drugs 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• OYHQOLUKZRVURQ-UHFFFAOYSA-M octadeca-9,12-dienoate Chemical compound CCCCCC=CCC=CCCCCCCCC([O-])=O OYHQOLUKZRVURQ-UHFFFAOYSA-M 0.000 description 1
• 229960005117 olmesartan Drugs 0.000 description 1
• VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 229950005564 patisiran Drugs 0.000 description 1
• 229960002582 perindopril Drugs 0.000 description 1
• IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
• 150000004713 phosphodiesters Chemical group 0.000 description 1
• 150000008298 phosphoramidates Chemical class 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
• 229920001308 poly(aminoacid) Polymers 0.000 description 1
• 229920001281 polyalkylene Polymers 0.000 description 1
• 229920000223 polyglycerol Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920002635 polyurethane Polymers 0.000 description 1
• 239000004814 polyurethane Substances 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 229960001233 pregabalin Drugs 0.000 description 1
• AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 229960001455 quinapril Drugs 0.000 description 1
• JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 229960003401 ramipril Drugs 0.000 description 1
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000008263 repair mechanism Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 229960003471 retinol Drugs 0.000 description 1
• 235000020944 retinol Nutrition 0.000 description 1
• 239000011607 retinol Substances 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 235000015598 salt intake Nutrition 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical class OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 229960002256 spironolactone Drugs 0.000 description 1
• LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 150000003432 sterols Chemical class 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 238000012385 systemic delivery Methods 0.000 description 1
• 229960005187 telmisartan Drugs 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000005309 thioalkoxy group Chemical group 0.000 description 1
• 150000003568 thioethers Chemical class 0.000 description 1
• 229940034208 thyroxine Drugs 0.000 description 1
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
• 229960004394 topiramate Drugs 0.000 description 1
• 229960005461 torasemide Drugs 0.000 description 1
• 238000002646 transcutaneous electrical nerve stimulation Methods 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 239000003744 tubulin modulator Substances 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 229960004699 valsartan Drugs 0.000 description 1
• SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
• 229960004688 venlafaxine Drugs 0.000 description 1
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 208000027121 wild type ATTR amyloidosis Diseases 0.000 description 1